FDA Clearance Tracker · P840024-S091
Nucleus 22 Cochlear Implant System
Last checked: Nov 20, 2026Latest source record: Jun 9, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jun 9, 2021
Approved
Time to decision
664 days
Received Aug 15, 2019. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P840024-S091
- Device name
- Nucleus 22 Cochlear Implant System
- Applicant
- Cochlear Americas
- Applicant location
- Lone Tree, CO
- Received
- Aug 15, 2019
- Decided
- Jun 9, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P840024
Device type
- Device type
- Implant, cochlear (MCM)
- Device class
- Class III
- Specialty
- Otolaryngology (ENT)
FDA's approval statement
As written in FDA's record.
Approval for labeling changes related to the MRI compatibility.
Source documents
Other decisions for Cochlear Americas
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260902 · Decided Jul 10, 2026 · 114 days after receipt
Device type: Active Implantable Bone Conduction Hearing System (PFO) · Otolaryngology (ENT)
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.